Status:

COMPLETED

Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Acquired Bleeding Disorder

Trauma

Eligibility:

All Genders

18-85 years

Brief Summary

This study is conducted in North America. The purpose of this study is to evaluate the occurrence and severity of bleeding in brain injury and to identify important safety issues following traumatic b...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Ages Eligible for Study: 18 Years - 85 Years

Exclusion

    Key Trial Info

    Start Date :

    October 6 2004

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    November 23 2005

    Estimated Enrollment :

    63 Patients enrolled

    Trial Details

    Trial ID

    NCT00124293

    Start Date

    October 6 2004

    End Date

    November 23 2005

    Last Update

    February 27 2017

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Novo Nordisk Investigational Site

    Plainsboro, New Jersey, United States, 08536

    2

    Novo Nordisk Investigational Site

    Mississauga, Canada, L4W 4XI

    Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury | DecenTrialz